Valuation dashboard for Enlivex Therapeutics Ltd. (ENLV) with P/E 0.00, P/B 0.00, EV/EBITDA -1.20 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.81, ENLV trades at a P/E of 0.00 and an ROE of 248.08%. Market capitalisation stands at $14M.
Balance sheet quality for ENLV: current ratio of 193.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.00 |
| EV / EBITDA | -1.20 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.58 |
| vs Current Price | -171.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ENLV | Enlivex Therapeutics Ltd. | $14M | 0.00 | 0.00 | 248.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.81 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IL |
Profitability
| Return on Equity | 248.08% |
| Return on Invested Capital | -0.49% |
| Return on Assets | 53.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN
Explore sector: Healthcare · Biotechnology
More sections of ENLV: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks